It also determined that CK1α facilitates AML by inhibiting p53 downstream of MDM2-mediated autophagy and apoptosis, suggesting that targeting CK1α presents a therapeutic opportunity for AML treatment. This evidence concerns the gene CSNK1A1 and acute myeloid leukemia.